

UPDATED ATAGI CLINICAL GUIDANCE ON VACCINATION AGAINST MONKEYPOX (MPOX)

Version 4.0
12 December 2022

Changes since previous version

- Updated recommendations for people with severe immunocompromise to now have the option to receive the JYNNEOS® vaccine via the intradermal route
- Updated list of conditions classified as severe immunocompromise
- Updated terminology on mpox vaccines for pre-exposure and post-exposure prophylaxis
- Updated guidance on risk-benefit assessment in pregnancy
- Updated co-administration guidance for COVID-19 vaccines
- Updated intradermal JYNNEOS® administration guidance, including injection sites and unsuccessful vaccination
- Addition of early vaccine effectiveness data from the 2022 global mpox outbreak
- New appendices on training resources for intradermal vaccine administration and multi-dose vial use

Summary

- This guidance is on the use of smallpox vaccines for protection against monkeypox virus infection. This advice will continue to be updated as new information emerges during the current multi-country mpox outbreak.
- Mpox is usually a self-limiting illness, and most people recover within a few weeks. However, severe illness can occur, particularly in immunocompromised people.
- Two vaccines are available in Australia for prevention of mpox: the 3rd generation JYNNEOS® (MVA-BN: modified vaccinia Ankara vaccine-Bavarian Nordic) and the 2nd generation ACAM2000™
- Limited supplies of the 3rd generation JYNNEOS® have been secured by the Commonwealth and some States and Territories. The initial distribution of JYNNEOS® in Australia is taking place through State- and Territory-based programs.

- JYNNEOS®:
 - JYNNEOS® is a highly-attenuated vaccine that is replication-deficient.
 - The primary course of JYNNEOS® is two doses, with a minimum dose interval of 28 days.
 - Standard administration of JYNNEOS® is by subcutaneous injection.
 - JYNNEOS® can be administered by intradermal injection as an alternative route for primary preventive vaccination (PPV, previously referred to as pre-exposure prophylaxis or PrEP). Each intradermal dose is 0.1mL (20% of the standard subcutaneous dose). The intradermal route is not preferred for the first dose of post-exposure preventive vaccination (PEPV, previously referred to as post-exposure prophylaxis or PEP).
 - JYNNEOS® is associated with fewer potential adverse events compared to ACAM2000™ and is safe to use in people with immunocompromise or atopic dermatitis. JYNNEOS® may also be used in children or during pregnancy, after a risk-benefit assessment.
- ACAM2000™:
 - ACAM2000™ is a live-attenuated vaccine that is replication-competent.
 - Specialised training and methods are required to administer ACAM2000™ by percutaneous scarification using a bifurcated needle, as a single dose.
 - Post-vaccination wound care is required for ACAM2000™ to protect vulnerable contacts and prevent self-inoculation from the vaccination site.
 - ACAM2000™ cannot be used in severely immunocompromised people (see Appendix A), people with active atopic dermatitis, in pregnancy or in infants under 12 months of age. It is associated with rare but serious adverse events.
- Overall, JYNNEOS® is the preferred vaccine for both PPV and PEPV, due to its more favourable safety profile and comparative ease of administration. Supply considerations may affect availability of JYNNEOS®. For healthy non-pregnant adults, where JYNNEOS® is not suitable or not available, ACAM2000™ has an established profile and may be considered for PPV or PEPV.
- The key risk groups recommended by Australian Technical Advisory Group on Immunisation (ATAGI) to receive vaccination are:
 1. Post-exposure preventive vaccination (PEPV): Anyone categorised by public health authorities as a high risk mpox contact in the past 14 days.
 2. Gay, bisexual and other men who have sex with men (GBMSM) at increased risk of mpox infection.

Proxy markers for increased risk of mpox infection may include:

- Those living with HIV.
 - A recent history of multiple sexual partners, participating in group sex, or attending sex on premises venues.
 - Other proxy markers, such as recent sexually transmitted infection or those being advised to take HIV PrEP due to number of sexual partners. Whilst many people prescribed HIV PrEP are monogamous with a HIV positive partner, this category can also capture those with multiple partners who are at high risk.
 - Recommendation from other service providers, such as sexual health clinics.
3. Sex workers, particularly those whose clients are in high-risk categories listed above.

4. Anyone in the above high-risk categories who is planning travel to a country experiencing a significant outbreak, or is planning to undertake high-risk activities while travelling, with vaccination recommended 4-6 weeks prior to departure.
 5. Anyone at greater risk of a poor clinical outcome from mpox infection, such as individuals with immunocompromise.
 6. Immunisation providers who are administering the ACAM2000™ vaccine.
- The risk-benefit assessment for individual vaccination is complex and depends on emerging epidemiology, exposure risk, contraindications and precautions, and alternative options to vaccination, such as antiviral agents in the post-exposure setting. Clinical resources are available to support this decision-making process.
 - Healthcare workers who will be administering the live replication-competent ACAM2000™ vaccine can be offered either vaccine if they have not previously received a smallpox vaccine.
 - In those individuals who have received a smallpox vaccine in the past, one booster dose is recommended if the previous dose of a smallpox vaccine was given more than ten years prior. JYNNEOS® (administered via either the subcutaneous or intradermal routes) and ACAM2000™ are both suitable vaccines for a booster.

Background

The virus and transmission

Monkeypox virus is a DNA virus in the Orthopoxvirus genus, which also includes the variola virus (which causes smallpox) and vaccinia virus (which is used in smallpox vaccines). The monkeypox virus was first discovered in 1958 and since then multiple outbreaks have been reported, mostly in western and central African nations including the Democratic Republic of the Congo and Nigeria. In 2003, there was an outbreak in the United States of America (USA) caused by imported rodents from Africa, in which cases were reported in both humans and pet prairie dogs¹. There are two genomic clades: clade I (formerly known as the Congo Basin or Central African clade) and clade II (formerly known as the West African clade) which is usually less severe. Mpox generally causes less severe disease than smallpox.

Monkeypox virus can be transmitted from infected animals to people, or from person to person. The natural animal reservoir for monkeypox virus remains unknown. Mpox does not spread easily between people. Transmission between people occurs via:

- Close contact with lesions or body fluids,
- Respiratory droplets in prolonged face-to-face contact or
- Fomites (such as contaminated clothing or linen).

Transmission can be prevented using [infection control measures](#).

Increasing numbers of cases of human mpox have been reported sporadically in non-enzootic countries over the last 2 years. On 11 May 2022, the World Health Organization alerted member states to a multi-country outbreak of mpox, originating from clade II of the virus². From 1 January to 31 October 2022, 77,264 laboratory-confirmed cases have been reported in 109 countries, with most cases in Europe and North America³. As of 3 November 2022, there have been 141 confirmed or probable cases of mpox reported in Australia⁴. Official case numbers are likely to be an underestimate, due to under-reporting.

Although anyone can contract mpox, global data in 2022 show higher levels of transmission within the sexual networks of gay, bisexual and other men who have sex with men (GBMSM).

Clinical features

The incubation period is between 5–21 days⁵. Mpox illness may begin with a prodrome of swollen lymph nodes, fever, headache, muscle aches, joint pain and back pain, followed by a rash within 1–3 days after fever onset. In typical cases, the rash tends to be more concentrated on the face and extremities rather than the trunk. However, in the current outbreak the rash was also observed in the genital, perianal and rectal areas, and may present as a single skin lesion⁶. Proctitis, which may be painful, has also been described⁷. The illness may also present without prodromal symptoms, with the rash being the first sign of infection⁸. The evolution of skin lesions typically progresses through four stages: macular, papular, vesicular, and pustular, before scabbing over. A person with mpox may be infectious from the onset of any symptoms until all scabs have fallen off, leaving intact skin underneath. Resolution of skin lesions may take up to four weeks from prodrome onset.

Mpox is usually self-limiting and most people recover within a few weeks⁵. The risk of severe disease and complications such as secondary infection, sepsis, pneumonia and encephalitis is likely to be increased in people with immunocompromise, young children and pregnant women, but can occur in anyone with mpox. Symptoms such as severe oropharyngeal or anorectal pain may also lead to hospitalisation⁶. Treatment with antiviral medication and vaccinia immune globulin (VIG) is available for people at risk of severe disease; refer to the National Treatment Guidelines.

Vaccine information

Smallpox vaccines contain the vaccinia virus, a poxvirus related to both smallpox and monkeypox viruses. Previous guidance in Australia and other countries on the use of smallpox vaccine has focused on protection against smallpox infection. Vaccines using the vaccinia virus for the prevention of smallpox are likely to be effective against mpox (refer to Vaccine effectiveness below).

There are two types of smallpox vaccine available in Australia for use against mpox:

- The third-generation vaccine: the replication-deficient modified vaccinia Ankara (MVA-BN) vaccine. The MVA-BN vaccine, known variously as JYNNEOS®/Imvamune/Imvanex (Bavarian Nordic), is registered for use in USA, United Kingdom, Canada and other countries for prevention of smallpox and mpox. Limited supplies of JYNNEOS® are available from the Commonwealth and via States and Territory programs.
- The second-generation vaccine containing replication-competent live attenuated vaccinia virus: ACAM2000™ (Emergent BioSolutions) is available from the National Medical Stockpile on a request basis for State and Territory programs.

Table 1: Summary of vaccine characteristics

Category	ACAM2000™	JYNNEOS®
Manufacturer	Emergent BioSolutions	Bavarian Nordic

Category	ACAM2000™	JYNNEOS®
Approved age for use*	≥18 years	≥18 years* Off-label paediatric use can be considered (see Precautions – JYNNEOS®)
Presentation	Multidose vial containing about 100 doses after reconstitution. Diluent supplied in separate vial.	Single dose vial containing 0.5mL each**
Volume/strength	1.0-5.0 x 10 ⁸ plaque-forming units (PFU)/mL or 2.5-12.5 x 10 ⁵ PFU/dose	At least 0.5 x 10 ⁸ infectious U/ 0.5 mL single dose
Primary schedule	1 dose	Subcutaneous route: 2 doses of 0.5mL each Intradermal route: 2 doses of 0.1mL each Doses should be at least 28 days apart. If the second dose is administered more than 28 days after the first dose, no additional repeat dose is required.
Administration route	Percutaneous (scarification)	Subcutaneous (SC) injection (standard route) Intradermal (ID) injection (alternative route) If a vaccine course is commenced using the subcutaneous route for the first dose, it can be completed by intradermal injection for the second dose, and vice versa.
Ingredients	2.5-12.5 x 10 ⁵ plaque forming units of live vaccinia virus per dose	0.5 x 10 ⁸ to 3.95 x 10 ⁸ infectious units of live modified vaccinia Ankara-Bavarian Nordic virus
Excipients	<ul style="list-style-type: none"> • 6-8 mM HEPES buffer (pH 6.5-7.5) • 2% albumin USP • 0.5 – 0.7% sodium chloride USP 	<ul style="list-style-type: none"> • 10 mM Tris (tromethamine) • 140 mM sodium chloride

Category	ACAM2000™	JYNNEOS®
	<ul style="list-style-type: none"> • 5% mannitol USP Diluent: <ul style="list-style-type: none"> • 50% (v/v) Glycerol USP • 0.25% (v/v) Phenol USP • Water 	May contain residual amounts of chicken host-cell DNA (≤ 20 mcg), chicken protein (≤ 500 mcg), benzonase (≤ 0.0025 mcg), gentamicin (≤ 0.163 mcg) and ciprofloxacin (≤ 0.005 mcg).

*JYNNEOS® is available for use in Australia under s18A (emergency use provision) of the Therapeutic Goods Act 1989. It is approved for use by the US FDA, UK MHRA and other regulatory bodies for use from ≥ 18 years.

**5 intradermal doses per standard 0.5mL vial.

Vaccine recommendations

Vaccination with either JYNNEOS® or ACAM2000™ may be used for both primary preventive vaccination (PPV) and post-exposure preventive vaccination (PEPV) against mpox. A shared clinical decision-making approach is appropriate, based on a joint assessment of individual risks, benefits and vaccine availability.

JYNNEOS® is the preferred vaccine for both PPV and PEPV, due to its more favourable safety profile and comparative ease of administration. For immunocompetent non-pregnant adults, where JYNNEOS® is not suitable or not available, ACAM2000™ may be considered for PPV or PEPV.

Intradermal administration of JYNNEOS® is an alternative route of administration to subcutaneous injection that is also a dose-sparing strategy. Intradermal administration is currently recommended for PPV only. Decisions around route of administration should consider contraindications and precautions, individual preferences, staff training, logistical factors and jurisdictional guidance.

Data from small studies suggest that immunogenicity of two primary doses of the MVA-BN vaccine, when administered intradermally (at 20% of standard dose; or 0.1mL) is similar to that when administered subcutaneously (at standard dose of 0.5mL), but with increased rate of local adverse events. However, intradermal injection is a specialised technique and there is a risk of inadvertent subcutaneous injection, leading to suboptimal immune responses. Programs considering intradermal vaccination should therefore ensure vaccinators are adequately supervised and trained prior to using this method (see Appendix B).

The subcutaneous and intradermal routes of administration for JYNNEOS® are considered to be interchangeable for the purpose of completing a two-dose course. If the first dose of JYNNEOS® is administered subcutaneously, the second dose can be administered via the intradermal route, and vice versa.

ACAM2000™ is associated with rare but serious adverse events and cannot be used in severely immunocompromised people (see Appendix A), in pregnancy, people with active eczema or in infants below 12 months of age. JYNNEOS® is associated with fewer potential adverse events and is safe to use in people with immunocompromise, for whom ACAM2000™ is contraindicated. JYNNEOS® should be used

in preference to ACAM2000™ for people with a history of eczema, in pregnancy and breastfeeding, and in children on an off-label basis, based on a risk-benefit assessment.

Individuals who are diagnosed with laboratory-confirmed mpox are not recommended to receive vaccination against mpox in the short to medium term after recovery, as their immunity will be boosted by natural infection.

Vaccination as primary preventive vaccination (PPV)

JYNNEOS® is preferred over ACAM2000™ for use for PPV. Prioritisation for PPV should take into account supply considerations, with at-risk population groups receiving priority over other groups, such as healthcare workers and laboratory workers, if supply is constrained. Individuals with severe immunocompromise (see Appendix A) should be prioritised to receive the second dose of JYNNEOS® as close to 28 days after the first dose as possible. Fractional dosing of JYNNEOS® at 20% of the standard dose via the intradermal route can be considered as a strategy to extend vaccine supply in all groups.

ATAGI recommends JYNNEOS® vaccination for:

- Gay, bisexual and other men who have sex with men (GBMSM) (age ≥16) at increased risk of mpox infection.

Proxy markers for increased risk of mpox infection may include:

- Those living with HIV.
 - A recent history of multiple sexual partners, participating in group sex, or attending sex on premises venues.
 - Other proxy markers, such as recent sexually transmitted infection or those being advised to take HIV PrEP due to number of sexual partners. Whilst many people prescribed HIV PrEP are monogamous with a HIV positive partner, this category can also capture those with multiple partners who are at high risk.
 - Recommendation from other service providers, such as sexual health clinics.
- Sex workers, particularly those whose clients belong to high-risk categories above.
 - Anyone in the above risk categories who is planning travel to a country experiencing a significant outbreak, or is planning to undertake high-risk activities while travelling, with vaccination recommended 4-6 weeks prior to departure.
 - Anyone at greater risk of a poor clinical outcome from mpox infection, such as individuals with immunocompromise.
 - Immunisation providers who are administering the ACAM2000™ vaccine.

Wider vaccination of low-risk GBMSM or the general population is not recommended at this time, due to the current epidemiology, low risk of infection and limited vaccine supply.

For individuals who have received a smallpox vaccine in the past (prior to the 2022 outbreak) and are currently recommended to receive vaccination, one booster dose is recommended if the previous dose of a smallpox vaccine was given more than ten years prior. The booster dose can be administered via either subcutaneous or intradermal routes.

Vaccination is recommended for healthcare workers who will be administering ACAM2000™ vaccine to others and who have not received a smallpox vaccine in the past. Those who have previously received a smallpox vaccine are likely to have some residual protection (see Vaccine effectiveness) but may consider receiving a dose of JYNNEOS® as a booster dose. Healthcare workers who will only be administering the JYNNEOS® vaccine and otherwise have no anticipated occupational exposure to monkeypox virus or other replication-competent Orthopoxviruses are not routinely recommended a smallpox vaccine.

Vaccination may also be considered for PPV for healthcare workers at higher risk of exposure to patients with mpox, including primary care, sexual health clinics, hospital staff and others, based on local risk assessments. The risk of transmission should be also minimised by using [infection control measures](#).

Laboratory workers working with smallpox or monkeypox virus, identified through local laboratory risk assessments, may also be considered for PPV. Refer to the PHLN Laboratory case definition document. Individuals working in these environments should review their own history of smallpox vaccination, as booster doses may be appropriate for those with new or ongoing risk of exposure to mpox⁹.

Previously vaccinated healthcare workers and laboratory workers with ongoing risk of occupational exposure may be considered for a booster. Supply of smallpox vaccines may impact the availability of vaccines for those at occupational risk, however, either of the current vaccines are appropriate for this indication following an individual risk-benefit discussion. A booster dose should be administered if the previous dose of a smallpox vaccine was given more than ten years prior. Subsequent boosters for those at continuing occupational risk should be given at ten-yearly intervals.

Vaccination for post-exposure preventive vaccination (PEPV)

PEPV should be considered as soon as possible after first exposure to a confirmed mpox case. Vaccination within 4 days of first exposure to an infectious case will provide the highest likelihood of prevention of disease. Vaccination between 4 to 14 days is anticipated to attenuate disease.

For guidance on who should consider receiving a smallpox vaccine (JYNNEOS® or ACAM2000™) for PEPV, seek the advice of the local Public Health Unit and refer to the [CDNA Monkeypox Virus Infection Series of National Guidelines](#). Individuals considered for vaccination for PEPV may include high-risk contacts who may be healthcare workers, household contacts, sexual contacts, or contacts in other settings where a risk for transmission has been identified. Individuals who have received a replication-competent smallpox vaccine (not MVA-BN) previously (prior to the 2022 outbreak), and who have been identified to be eligible for PEPV, should receive PEPV vaccination as soon as possible, regardless of the timing of the previous smallpox vaccine dose.

JYNNEOS® is the preferred vaccine for PEPV. Where a decision is made to provide PEPV, and JYNNEOS® is to be used, a single dose of JYNNEOS® should be given via the subcutaneous route. If mpox infection has not occurred and there is an ongoing exposure risk, the second dose of JYNNEOS® should be given from at least 28 days after the first, as completion of a primary course for long-term protection. The second dose may be given as either 0.5mL via the subcutaneous route or 0.1mL via the intradermal route.

A single dose is recommended if ACAM2000™ is used for PEPV, noting this vaccine is contraindicated if the individual is immunosuppressed.

Risk-benefit considerations for vaccination

A recommendation for vaccination should be based on shared decision-making between the patient and clinician. When considering vaccinating for either PPV or PEPV, the following factors should be considered:

- Severity of mpox: Mpox in humans is generally self-limiting and is less severe than smallpox, although lesions may be painful and require supportive treatment, including hospital admission. Overall case fatality rates ranged from around 3-10% in a recent review of outbreaks in the West and Central African settings¹⁰. In the first 25,000 cases reported in European Union/European Economic Area countries, there have been four deaths and six ICU admissions¹¹.
- Individual risk factors for severe mpox, noting that some conditions may also be absolute or relative contraindications to vaccination with ACAM2000™, e.g. immunocompromise, pregnancy (see below).
- Availability of treatment for mpox such as antiviral therapy or vaccinia immune globulin; refer to [National Treatment Guidelines](#).
- Individual risk factors for adverse events from vaccination, especially with ACAM2000™ e.g., immunocompromise (see [Appendix A](#)), eczema, cardiac disease, pregnancy (see below), young age, but also with intradermal administration of JYNNEOS® e.g., history of keloid scarring (refer to [Contraindications and Precautions](#)).
- Frequency and severity of adverse events after vaccination with either of the vaccines, noting evidence suggesting a lower rate of adverse events following JYNNEOS® compared to ACAM2000™, and availability of treatment for adverse events related to the vaccine.
- Prior vaccination with a smallpox vaccine and the potential benefit of revaccination or a booster dose (refer to [vaccine effectiveness](#) section).
- Relatively more direct evidence demonstrating effectiveness in disease prevention from replication-competent vaccine (such as ACAM2000™) compared with JYNNEOS®.
- Timing when maximum protection is conferred after a primary dose/series (about 4 weeks after a single dose of ACAM2000™, compared with about 2 weeks after the second dose of JYNNEOS®)
- Timing of first and last exposure to the monkeypox virus, if considering PEPV.
- Specific considerations for pregnancy: safety data for the use of JYNNEOS® in pregnancy is limited, but with no concerns identified to date. Any decision on the use of vaccine should take into account the likelihood of mpox infection in pregnancy and the risks to both the mother and the fetus. A small case series from the DRC followed four women who were diagnosed with mpox in the first and second trimesters of pregnancy, with three of the pregnancies resulting in miscarriage or stillbirth¹². In the current 2022 outbreak, the US CDC reports 17 confirmed or probable cases of mpox infection occurring during pregnancy, with ongoing follow-up to identify potential sequelae¹³. Limited data from Brazil suggest that nine pregnant women diagnosed with mpox had similar clinical outcomes compared to non-pregnant women, but there was very limited information on outcomes in the fetus or infant¹⁴.

Key vaccine characteristics relevant to decision-making are summarised in Table 2.

Table 2: Key characteristics of ACAM2000™ and JYNNEOS® relevant to shared decision making

Characteristic	ACAM2000™	JYNNEOS®
Safety in people with immunocompromise	Contraindicated – contains live replication-competent virus	Considered safe to use

Characteristic	ACAM2000™	JYNNEOS®
(see Appendix A for list)		
Safety in pregnancy	Contraindicated – contains live replication-competent virus	Considered safe to use
Safety in children	Not formally studied in children aged <18 years, however, there was widespread use of first generation live attenuated vaccinia vaccines in the past in this age group. Contraindicated for age <1 year.	Not formally studied in children <18 year (and not registered for use in children in regions where JYNNEOS® is registered), however, there are trial data on safety in children on MVA used as the vector for a small number of childhood vaccines; can be considered in this age group using risk-benefit assessment, especially for individuals in high-risk groups ≥16 years of age.
Safety in people with eczema / atopic dermatitis	Absolute contraindication in people with active atopic dermatitis. Relative contraindication in people with a past history of atopic dermatitis but without current disease activity – Risk of serious adverse events	Safe to use
Safety in people with history of keloid scarring	Precaution – case reports of people developing keloid scarring at inoculation sites with percutaneously administered smallpox vaccines	Intradermal route: precaution in this group, due to increased risk of scarring at vaccination site Subcutaneous route: safe to use
Safety in people with vulnerable close contacts	Precaution – risk of serious adverse events	Safe to use
Risk of myocarditis or pericarditis	Yes – refer to Adverse Events	Insufficient data to assess risk Not reported in clinical studies*

Characteristic	ACAM2000™	JYNNEOS®
Risk of other serious adverse events	Yes – refer to Adverse Events	No other notable serious adverse events based on available data
Co-administration	In people at risk of myo/pericarditis, for PPV purposes only, consider separating ACAM2000™ and any COVID-19 vaccines by 2 weeks	Considered safe to co-administer* JYNNEOS® and COVID-19 vaccines do not need to be separated unless there is a specific clinical concern (see Co-administration).

*One case of possible pericarditis, with suggestive evidence of an alternative viral infection as the potential cause, was identified among >7800 recipients of MVA-BN vaccines (including JYNNEOS®) across multiple clinical studies¹⁵

During the shared clinical decision making and consent process, patients should also be informed of the following:

For either ACAM2000™ or JYNNEOS® vaccination

Potential serious and mild adverse events (refer to [Adverse Events](#) below)

For ACAM2000™ only:

- Expected vaccine reaction, including permanent scar
- Aftercare instructions, including wound care
- Precautions to minimise risk of autoinoculation or transmission of vaccine virus to others
- For women of childbearing potential: the need to avoid pregnancy for 28 days following vaccination. If ACAM2000™ is inadvertently given to a pregnant woman, seek expert advice via your state or territory health department.

Vaccine Contraindications and Precautions

CONTRAINDICATIONS

JYNNEOS®

Contraindications include anaphylaxis to a previous dose or to a component of the vaccine.

JYNNEOS® contains benzonase, gentamicin and ciprofloxacin.

See [JYNNEOS® consent template](#).

ACAM2000™

Absolute contraindications to ACAM2000™ include:

- Anaphylaxis to previous dose or to a component of the vaccine (including neomycin or polymyxin B sulfate)

- Severe immunocompromise, particularly defects in cellular immunity. For detailed guidance on which conditions and medications cause severe immunocompromise, see Appendix A.
- Pregnancy (women of child-bearing age should avoid pregnancy for 28 days after vaccination)
- Age under 12 months
- Presence of active dermatitis (including eczema) or other active exfoliative skin conditions

People in the following groups should be viewed as having relative contraindications, depending on their detailed clinical history and the risks for vaccine-related adverse events (as well as from the risk for MPX):

- Mild or moderate immunocompromise, including secondary to treatment or disease
- Eye disease treated with topical steroids
- Age 12 months to <18 years
- Past history of atopic dermatitis or other exfoliative skin conditions, without current disease activity. People with inactive atopic dermatitis may be administered ACAM2000™, followed by careful monitoring and active follow up. Refer to the National Treatment Guidelines for treatment of serious vaccine-related complications.

PRECAUTIONS

JYNNEOS®

Specific points to note:

- People who are pregnant or breastfeeding. JYNNEOS® has not been formally evaluated in pregnant or lactating women, but there are no theoretical safety concerns relating to its use in these groups.
- Children under 18 years of age. JYNNEOS® has not been approved for use in individuals under 18 years of age in regions/countries where it is registered. There are limited safety data for this age group. However, paediatric studies of other vaccines using MVA as a vector have not demonstrated significant safety concerns¹⁶⁻¹⁸. In the current outbreak, people in high-risk GBMSM groups ≥16 years of age are recommended to receive vaccination as potential benefits outweigh potential risks.
- Individuals with atopic dermatitis reported a higher frequency of local and general symptoms after vaccination compared with those without this condition.
- JYNNEOS® may contain trace residues of chicken egg protein and for individuals with confirmed anaphylaxis to egg; there is a theoretical risk of allergic reaction.
- Individuals with a history of keloid scarring are not recommended to receive JYNNEOS® via the intradermal route. The subcutaneous route is preferred.
- Lower immune response has been observed in HIV infected individuals compared to individuals without HIV, but clinical relevance is unknown. A key study examining safety and immunogenicity of MBV-BN in people living with HIV did not separate out its effects in the subset of participants with CD count of <200 at the time of vaccination¹⁹. There are no data on the immune response to JYNNEOS® in other immunosuppressed individuals²⁰.

ACAM2000™

The risk for adverse events may be higher for the following individuals (refer to Adverse Events) or their household contacts, and this needs to be considered in the risk-benefit assessment.

- People who are breastfeeding, where the risk is to the infant via documented vaccinia virus shedding through breastmilk
- People with cardiac disease/cardiac risk factors. Major cardiac risk factors include hypertension, diabetes mellitus, hypercholesterolemia, heart disease at age ≤ 50 years in a first-degree relative, and smoking. The presence of three or more of these factors is considered a relative contraindication to primary vaccination with ACAM2000™.
- People with vulnerable household contacts (e.g., immunocompromised, people with eczema active exfoliative skin conditions, pregnant individuals), noting the risk of onward transmission to others can be minimised (refer to Aftercare).

Vaccine administration and aftercare

JYNNEOS®

The standard route of administration for JYNNEOS® is by subcutaneous (SC) injection, with two doses (0.5 mL each) at least 28 days apart. Each subcutaneous dose (0.5 mL) is supplied in a single-dose vial.

An alternative route of administration for JYNNEOS® (for PPV only, see Vaccine Recommendations) is by intradermal (ID) injection, with two doses of 0.1mL each (20% of the standard subcutaneous dose) 28 days apart. Each dose needs to be withdrawn from the standard subcutaneous-dose vial (see Appendix C for more information on multi-dose vial use of JYNNEOS®). Immunisation providers should be trained to administer JYNNEOS® by intradermal injection. Evidence informing the intradermal use recommendation was based on vaccine administration at the inner aspect of the forearm. However, other administration sites, such as the deltoid or the upper back below the scapula, are also acceptable (see Appendix B for suggested training resources for intradermal administration).

If an intradermal dose is administered incorrectly (e.g. inadvertently given subcutaneously), the recommendation is to administer a repeat dose as soon as possible. No more than one additional intradermal injection should be attempted, by a vaccinator who is confident in the technique. Alternatively, give a 0.5mL dose subcutaneously (withdrawn from a new vaccine vial).

No specialised aftercare is required. Refer to Product Information. The second dose does not need to be repeated if given later than 28 days after the first dose.

ACAM2000™

Detailed information on ACAM2000™ administration and aftercare is available in the Product Information and the Consumer Medicines Information sheet, accessible at the TGA website.

ACAM2000™ is supplied in multi-dose vials, each containing approximately 100 doses after reconstitution. Specialised trained vaccinators administer ACAM2000™ with a bifurcated needle using a technique called scarification. The virus replicates at the injection site, causing a localised infection (“pock”) around 10 days after inoculation. The vaccine has “taken”, or been successful, if a red itchy spot is present 4 days following vaccination. A blister then develops and forms a scab that falls off in the third week, leaving a small scar. When choosing the vaccination site, consider the practicality of keeping the area covered.

Aftercare following ACAM2000™ administration

Prior to vaccination, vaccine recipients should be informed about expected reactions and aftercare. They should also be informed about the potential for serious adverse events and how to seek care if concerning symptoms develop (refer to [Adverse Events](#)).

- The expected reaction to vaccination is a papule (small bump) at the vaccination site on day 2 to 5 post vaccination, which progresses to a vesicle (blister), then pustule (blister with pus), and then a scab.
- The scab typically separates within 14-21 days, leaving a pitted scar.
- The vaccination site wound is infectious until scabbing occurs and must be covered with a gauze bandage secured with adhesive tape, to prevent a risk of auto-(self) inoculation onto skin in other sites or transmission of the vaccinia virus to others. An occlusive dressing can be used to minimise risk of transmission to vulnerable close contacts.
- Wound dressings should be changed every 1 to 3 days disposed of in sealed plastic bags and can then be disposed of in general rubbish.
- Avoid contact with individuals at high risk of serious adverse effects of vaccinia virus, for instance, those with eczema or other exfoliative skin lesions, immunodeficiency states including HIV infection, pregnant people or infants less than 12 months of age.
- Vaccinated healthcare workers should avoid contact with immunocompromised patients and high-risk areas (e.g., haematological oncology and transplant wards) until the scab has separated. When caring for patients, ensure the vaccination site is well covered with an occlusive wound dressing and follow good hand washing technique.
- Blood and organ donation should be avoided for at least 30 days following vaccination.
- Pregnancy should be avoided for at least 28 days following vaccination.
- Refer to Product Information and the Consumer Medicines Information sheet for further information.

Co-administration of ACAM2000™ or JYNNEOS® with COVID-19 or other vaccines

There is a rare risk of associated myocarditis and/or pericarditis following either ACAM2000™ or COVID-19 vaccines, respectively, especially in people under 40 years of age and in males. Based on the theoretical risk of myocarditis and pericarditis, when used as PPV, spacing ACAM2000™ and a COVID-19 vaccine apart by two weeks may be considered. This may theoretically reduce the risk of myocarditis and pericarditis, but there is no evidence to confirm this. Any decision to delay administration should be balanced against the need for earlier protection and the potential to miss an opportunity to vaccinate.

It is not known if JYNNEOS® is associated with a risk of myocarditis. In cases of specific clinical concern, spacing JYNNEOS® and a COVID-19 vaccine apart by two weeks may be considered.

Adverse events

JYNNEOS®

JYNNEOS® vaccine is associated with fewer adverse events than ACAM2000™. A phase 3 trial showed fewer minor and serious adverse events in participants who received JYNNEOS® (via the subcutaneous

route) than in those who received ACAM2000™ (17 out of 220 versus 64 out of 213 participants with adverse events of grade 3 or higher, P<0.001)²¹.

Safety data for JYNNEOS® are available from a pooled analysis of 22 clinical studies which included over 7800 participants who received an MVA-BN vaccine²². Adverse events in persons previously vaccinated with a smallpox vaccine compared with those never vaccinated occurred at similar frequencies after MVA-BN was given (Table 3)²².

Table 3 - Adverse events following vaccination with MVA-BN (JYNNEOS®) via subcutaneous route (0.5mL)²²

	Frequency in vaccine-naïve individuals	Frequency in previously vaccinated individuals
Common local adverse events		
Injection site pain	85%	80%
Injection site redness	61%	81%
Injection site swelling	51%	67%
Induration	45%	70%
Injection site itch	43%	32%
Common systemic adverse events		
Muscle aches	43%	22%
Headache	35%	28%
Fatigue	30%	34%
Nausea	17%	10%
Chills	10%	0.7%
Fever	2%	0.5%

The safety of the intradermal route of administration of the MVA-BN vaccine was assessed in a phase II study compared with subcutaneous administration²³. There were no significant differences in the frequency of systemic adverse events between the intradermal and subcutaneous groups. However, local reactogenicity, assessed through measurements of erythema and induration, was higher in the intradermal group compared to those in the subcutaneous group for both doses of the vaccine. Three participants in the intradermal group also reported severe itch at the injection site. Intradermal dosing is now also used in the US and EU countries as a dose-sparing strategy for MVA-BN^{24,25}.

[AusVaxSafety](#) is an Australian active surveillance system monitoring adverse events after immunisation, that has been used to monitor JYNNEOS vaccine safety in the 2022 mpox outbreak²⁶. Early AusVaxSafety data collected to November 2022 show that most adverse events reported after JYNNEOS® administration (either via subcutaneous or intradermal route) have been mild and local to the injection site.

ACAM2000™

Adverse events after ACAM2000™ in clinical studies were common but were generally mild to moderate. (Refer to the Product Information for further information.)

Common local adverse events included:	Common systemic adverse events included:
<ul style="list-style-type: none"> • A permanent pitted scar at the injection site is universal following successful inoculation • Injection site itch (92%) • Injection site redness (74%) • Injection site pain (67%) • Lymph node pain (57%) • Injection site swelling (48%) 	<ul style="list-style-type: none"> • Headache (50%) • Fatigue (48%) • Muscle aches (46%) • Malaise (37%) • Feeling hot (32%) • Nausea (19%) • Diarrhoea (16%)

Serious adverse events

ACAM2000™ is associated with a risk of myocarditis and pericarditis. The risk is highest in young adults and in males, with overall incidence of around 1 in 5000 to 1 in 12,800 doses based on post-licensure passive surveillance in military personnel^{27,28}. Of the 180 cases reported in one cohort study, 21% were subclinical myopericarditis, 22% were myocarditis, 27% were pericarditis and 29% were clinical myopericarditis²⁷. In a case series of 18 cases, the mean time to onset was 10 days²⁸.

Other serious adverse events have been historically associated with replication-competent smallpox vaccines, including the first-generation vaccine Dryvax, and are listed below. Accurate rate estimates of these adverse events for ACAM2000™ are not available given its limited use, but they are a potential risk. Recommendations for treatment of serious adverse events with VIG and/or antiviral agents are outlined in the [National Treatment Guidelines](#).

- Accidental autoinoculation is the unintentional transfer of vaccinia virus from the vaccination site to elsewhere on the body, which can produce a vaccinia rash at distant sites.
- Autoinoculation of the eye may result in vaccinia keratitis. There are no current disease-specific treatment options available for the management of vaccinia keratitis²⁹.
- Eczema vaccinatum involves widespread pustular/erosive lesions from the vaccinia virus, occurring particularly in areas affected by eczema/atopic dermatitis.
- Generalised vaccinia results from viraemia and presents with a generalised vaccinia virus rash. It can be accompanied by fever, myalgia and headache, but is self-limiting in immunocompetent hosts. Generalised vaccinia is thought to be rare but has been reported after ACAM2000™³⁰.
- Progressive vaccinia presents with delayed/absent local wound healing and widespread lesions emanating from the inoculation site that can become necrotic. The incidence of this during the

smallpox vaccination era was 1 per million doses³¹. The risk is highest in people with severe immunocompromise, particularly those with defective cell-mediated immunity.

- Fetal vaccinia resulting from vaccination during pregnancy, which can result in stillbirth or perinatal death.
- Serious neurological adverse events including encephalitis, post-vaccinial encephalopathy (PVE) and encephalomyelitis (PVEM).

As there are limited safety data from large population-based programs for ACAM2000™ and JYNNEOS®, it is important to ensure there is ongoing phase IV (post marketing) vaccine safety monitoring for both vaccines, utilising Australian adverse event surveillance systems. ATAGI recommends that these reports be collated at a jurisdictional and national level, utilising international frameworks for smallpox vaccine reporting³².

Individuals who develop any adverse events following immunisation (AEFI) with a smallpox vaccine should be encouraged to report data on the event(s) to their healthcare provider, who in turn report to the State/Territory and the TGA. Active surveillance for AEFI with smallpox vaccines is also encouraged, using established systems such as AusVaxSafety.

Vaccine effectiveness

There is evidence that demonstrates the effectiveness of replication-competent smallpox vaccines (such as Dryvax or ACAM2000™) against smallpox or mpox, when used for primary preventive or post-exposure preventive vaccination. There are no direct data on the effectiveness of JYNNEOS® against smallpox, and only preliminary direct data on effectiveness against mpox from the current outbreak. Vaccine effectiveness is inferred from indirect evidence, particularly immunogenicity data.

Effectiveness of ACAM2000™ and JYNNEOS® for primary preventive vaccination against mpox

Active mpox surveillance data from the Democratic Republic of the Congo (DRC) in 2005–2007 demonstrated that among individuals born before 1980 (when the official national mass smallpox vaccination program ended), people vaccinated against smallpox had a 5.2-fold lower risk of mpox than those unvaccinated (0.78 vs. 4.05 per 10,000), giving a smallpox pre-exposure vaccine effectiveness against mpox of 80.7% (95% CI: 68.2–88.4%)³³.

Vaccine efficacy against smallpox by first generation smallpox vaccines such as Dryvax has not been assessed in randomised controlled studies. After administration of a standard dose of smallpox (vaccinia virus) vaccine, >95% of primary vaccinees exhibit neutralising or hemagglutination inhibition antibody against smallpox at a titre of $\geq 1:10$ ^{34,35}. Additionally, clinical effectiveness of first-generation smallpox vaccines, leading to global eradication of smallpox, has been shown. Immunogenicity data for the second-generation vaccine, ACAM2000™, assessed immune responses following inoculation against smallpox virus rather than monkeypox virus, and in randomised controlled trials ACAM2000™ demonstrated similar cellular immune responses against smallpox virus as Dryvax. On the basis of all immunogenicity results, ACAM2000™ is considered to be non-inferior to Dryvax against smallpox³⁵ and can be inferred to be similarly effective against other poxviruses including monkeypox.

Vaccine effectiveness for the third generation MVA-BN vaccine (including JYNNEOS®) against smallpox was inferred by comparing the immunogenicity of MVA-BN to that of ACAM2000™ using plaque reduction neutralization testing (PRNT) against vaccinia virus. In a phase 3 trial of 440 participants randomised to two doses of MVA-BN followed by ACAM2000™ versus one dose of ACAM2000™, the immune responses in the MVA-BN group, after two doses of MVA-BN and prior to the challenge with ACAM2000™, were similar to those who had received one dose of ACAM2000™ only^{20,21}.

Additionally, evidence for the use of smallpox vaccines against mpox was informed by challenge studies in macaques. In one study, three groups of macaques were vaccinated using 1 dose of ACAM2000™, 1 dose of MVA-BN or 2 doses of MVA-BN. After challenge with a lethal dose of monkeypox virus at 28 days following the last vaccine dose, vaccine efficacy against death compared to an unvaccinated control group was 100% for the ACAM2000™ and 2-dose MVA-BN groups, and 67% for the 1-dose MVA-BN group³⁶.

Effectiveness after one dose of MVA-BN

In the 2022 global mpox outbreak, vaccine shortage has led to many jurisdictions prioritising the first dose of the MVA-BN vaccine, delaying the second dose until supply improves. Early US data from 90 people with mpox identified that 69 (77%) of infections occurred in day 1-14 after vaccination, suggesting that the vaccine may be more effective after peak immune response is reached at 14 days. Among the remaining cases, eight occurred more than 28 days after dose 1 of JYNNEOS®, with two cases occurring at least 3 weeks following a second dose.

A cohort study undertaken in Israel followed 1,970 MVA-BN vaccine-eligible males aged 18-24, with 873 of these individuals receiving the vaccine and completing at least 25 to 34 days of follow-up³⁷. In this population, the vaccine effectiveness of one dose of MVA-BN was estimated to be 79% (95% CI 24% to 94%).

Intradermal administration

Evidence supporting intradermal administration comes particularly from a 2015 phase II randomised study with 524 participants²³. The control group received the standard (0.5mL) dose of MVA-BN vaccine administered by the subcutaneous route, and the intervention group received 20% (0.1 of the standard dose) of the MVA-BN vaccine administered intradermally, with 2 doses 28 days apart. Peak neutralising antibody titres against the vaccinia virus after 2 doses of MVA-BN via the intradermal route were shown to be non-inferior to titres after 2 doses of MVA-BN via subcutaneous administration.

Persistence of immune response

A systematic review on duration of immunity published in 2019 suggests that some protection against smallpox virus may persist for greater than 20 years after smallpox vaccination³⁸. It is unclear how these data can be extrapolated to infer the duration of protection against mpox.

In the 2022 mpox outbreak, early data from Spain include a case series with 181 confirmed mpox cases diagnosed May-June 2022, where 32 (18%) of cases self-reported prior smallpox vaccination³⁹.

Clinical studies have shown evidence of protection against the vaccinia virus at 2 years following a primary course of the MVA-BN vaccine²⁰. A single booster dose of MVA-BN at 2 years led to a slight improvement in immune response another 2 years later, among people who had also received a primary

course of the MVA-BN vaccine. The duration of protection after 1 primary dose of MVA-BN is currently not known beyond 4 weeks.

Vaccine effectiveness for post-exposure preventive vaccination (PEPV)

Vaccination with a smallpox vaccine following exposure to mpox may prevent or attenuate the infection, based on extrapolation from low-quality historical data of protection against smallpox, animal models, and more recent use in isolated outbreaks of mpox in non-endemic countries.

A 2019 review of human smallpox outbreak data from year 1882 to 1973 calculated an overall effectiveness of PEPV against smallpox with any smallpox vaccine of 45% (IQR 25.5% to 64.5%), noting wide variation in timing of vaccination after exposure⁴⁰. A study obtaining consensus opinions from experts using the Delphi technique estimated the effectiveness of post-exposure smallpox vaccination in preventing disease at 1–3 days after exposure to be 80%⁴¹.

There are insufficient data to specifically estimate effectiveness against mpox, though a range of first, second and third-generation smallpox vaccines have been used as PEPV for mpox in outbreaks of mpox in non-endemic countries since 2003⁴²⁻⁴⁵. Breakthrough mpox cases have occurred after PEPV vaccination of high-risk contacts with Dryvax and with MVA-BN.

The effectiveness of post-exposure use of ACAM2000™ and JYNNEOS® against mpox was compared directly in one animal study only, using prairie dogs. At day 7 following vaccination, animals vaccinated with one dose of ACAM2000™ one day after exposure to the monkeypox virus had higher antibody titres than those receiving one dose of JYNNEOS® one day after exposure, suggesting a more rapid immune response after ACAM2000™. While the difference in antibody titres was not statistically different at day 14 following vaccination, no correlate of protection in this species is known⁴⁶.

This comparable immunogenicity after a single dose of MVA-BN (including JYNNEOS®) with that of ACAM2000™ (for which there is indirect evidence for effectiveness when used for PEPV), indirectly suggests some effectiveness can be expected after a single dose of MVA-BN given as PEPV. Various animal studies with the monkeypox (and mousepox) viruses, using mostly the MVA-BN vaccine, corroborate the finding that vaccine effectiveness as PEPV begins to decline over time (e.g. when given at 3 days post-exposure, effectiveness is lower than when given at 1 day post-exposure).

Vaccine storage and handling

JYNNEOS®

(Refer to the Product Information for further information.)

Packaging

JYNNEOS® is supplied in packages of 20 single standard subcutaneous-dose vials.

Storage

Contact the relevant State/Territory authority for detailed information about storage as it can vary across jurisdictions due to the conditions under which vaccines are transported and stored. Refer to Appendix D for State/Territory contact details.

If the vaccine is distributed thawed, it should be stored at refrigerator temperature and not re-frozen.

Once the vial is punctured and a dose is withdrawn, if it is not used in its entirety, it should be stored at +2°C to +8°C and discarded within 8 hours of the first puncture. See Appendix C for specific guidance on using the standard subcutaneous-dose vial for multiple intradermal doses.

Disposal

Equipment used for JYNNEOS® vaccination, including used vials, should be disposed of as medical waste.

ACAM2000™

(Refer to the [Product Information](#) for further information.)

Packaging

The live vaccinia virus component of the ACAM2000™ vaccine is supplied in multiple-dose 3 mL clear glass vials containing lyophilised powder (freeze-dried vaccine). Diluent for ACAM2000™ is supplied in 3 mL clear glass vials containing 0.6 mL of diluent. Bifurcated needles are supplied in boxes (5 x 5 x 1 in) containing 100 needles. 1 mL tuberculin syringes with 25-gauge x 5/8" needles are supplied for vaccine reconstitution.

Storage

ACAM2000™ should be stored in a freezer with an average temperature of -15°C to -25°C. After reconstitution, ACAM2000™ vaccine may be administered during 8 hours at +20°C to +25°C. Reconstituted ACAM2000™ vaccine may be stored in a refrigerator at +2°C to +8°C for no longer than 30 days, after which it should be discarded. Diluent for ACAM2000™ should be stored at +15°C to +30°C. ACAM2000™ contains live vaccinia virus that is transmissible, and should be handled as an infectious agent once vials are open.

Disposal

The ACAM2000™ vaccine vial, its stopper, the diluent syringe, the vented needle used for reconstitution, the bifurcated needle used for administration, and any gauze or cotton that came in contact with the vaccine should be discarded in leak-proof, puncture-proof biohazard containers. These containers should then be disposed of appropriately.

References

1. Reynolds MG, Yorita KL, Kuehnert MJ, et al. Clinical Manifestations of Human Monkeypox Influenced by Route of Infection. *The Journal of Infectious Diseases* 2006;194:773-80.
2. World Health Organization. Meeting of the International Health Regulations (2005) Emergency Committee regarding the multi-country monkeypox outbreak. 2022. Available from: [https://www.who.int/news/item/25-06-2022-meeting-of-the-international-health-regulations-\(2005\)-emergency-committee--regarding-the-multi-country-monkeypox-outbreak](https://www.who.int/news/item/25-06-2022-meeting-of-the-international-health-regulations-(2005)-emergency-committee--regarding-the-multi-country-monkeypox-outbreak) (Accessed 21/07/2022).
3. World Health Organization. Multi-country outbreak of monkeypox, External situation report #9 - 2 November 2022. 2022. Available from: <https://www.who.int/publications/m/item/multi-country-outbreak-of-monkeypox--external-situation-report--9---2-november-2022> (Accessed 09/11/2022).
4. Australian Government Department of Health and Aged Care. Monkeypox (MPX) health alert.2022. Available from: <https://www.health.gov.au/health-alerts/monkeypox-mpx/about> (Accessed 09/11/2022).
5. World Health Organization. Clinical management and infection prevention and control for monkeypox: Interim rapid response guidance, 10 June 2022.2022. Available from: <https://www.who.int/publications/i/item/WHO-MPX-Clinical-and-IPC-2022.1> (Accessed 22/07/2022).
6. Thornhill JP, Barkati S, Walmsley S, et al. Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022. *New England Journal of Medicine* 2022.
7. Centers for Disease Control and Prevention. What Clinicians Need to Know About Monkeypox in the United States and Other Countries. 2022. Available from: https://emergency.cdc.gov/coca/ppt/2022/052422_slides.pdf (Accessed 21/07/2022).
8. Girometti N, Byrne R, Bracchi M, et al. Demographic and clinical characteristics of confirmed human monkeypox virus cases in individuals attending a sexual health centre in London, UK: an observational analysis. *The Lancet Infectious Diseases*.
9. Rao A, Petersen B, Whitehill F, et al. Use of JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) for Preexposure Vaccination of Persons at Risk for Occupational Exposure to Orthopoxviruses: Recommendations of the Advisory Committee on Immunization Practices—United States, 2022. *MMWR Morb Mortal Wkly Rep* 2022;71.
10. Bunge EM, Hoet B, Chen L, et al. The changing epidemiology of human monkeypox-A potential threat? A systematic review. *PLoS neglected tropical diseases* 2022;16:e0010141-e.
11. European Centre for Disease Prevention and Control. Joint ECDC-WHO Regional Office for Europe Monkeypox Surveillance Bulletin. 2022. Available from: <https://monkeypoxreport.ecdc.europa.eu/> (Accessed 24/11/2022).

12. Mbala PK, Huggins JW, Riu-Rovira T, et al. Maternal and Fetal Outcomes Among Pregnant Women With Human Monkeypox Infection in the Democratic Republic of Congo. *The Journal of Infectious Diseases* 2017;216:824-8.
13. Centers for Disease Control and Prevention. Technical Report 4: Multi-National Monkeypox Outbreak, United States, 2022. 2022. Available from: <https://www.cdc.gov/poxvirus/monkeypox/cases-data/technical-report/report-4.html> (Accessed 07/11/2022).
14. Khalil A, Samara A, O'Brien P, et al. Monkeypox in pregnancy: update on current outbreak. *The Lancet Infectious Diseases* 2022;22:1534-5.
15. Overton ET, Lawrence SJ, Wagner E, et al. Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial. *PLoS ONE* 2018;13.
16. Afolabi MO, Tiono AB, Adetifa UJ, et al. Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants. *Mol Ther* 2016;24:1470-7.
17. Ota MO, Odutola AA, Owiafe PK, et al. Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants. *Sci Transl Med* 2011;3:88ra56.
18. Tameris MD, Hatherill M, Landry BS, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. *The Lancet* 2013;381:1021-8.
19. Overton ET, Lawrence SJ, Stapleton JT, et al. A randomized phase II trial to compare safety and immunogenicity of the MVA-BN smallpox vaccine at various doses in adults with a history of AIDS. *Vaccine* 2020;38:2600-7.
20. European Medicines Agency. Assessment report IMVANEX. 2013. Available from: ema.europa.eu/en/documents/assessment-report/imvanex-epar-public-assessment-report_en.pdf (Accessed 16/06/2022).
21. Pittman PR, Hahn M, Lee HS, et al. Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox. *New England Journal of Medicine* 2019;381:1897-908.
22. US Food and Drug Administration. JYNNEOS- FULL PRESCRIBING INFORMATION Package Insert. 2018. Available from: <https://www.fda.gov/media/131078/download> (Accessed 27/05/2022).
23. Frey SE, Wald A, Edupuganti S, et al. Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects. *Vaccine* 2015;33:5225-34.
24. Centers for Disease Control and Prevention. JYNNEOS Vaccine. 2022. Available from: <https://www.cdc.gov/poxvirus/monkeypox/interim-considerations/jynneos-vaccine.html#admin> (Accessed 19/08/2022).

25. European Medicines Agency. EMA's Emergency Task Force advises on intradermal use of Imvanex / Jynneos against monkeypox. 2022. Available from: <https://www.ema.europa.eu/en/news/emas-emergency-task-force-advises-intradermal-use-imvanex-jynneos-against-monkeypox> (Accessed 22/08/2022).
26. AusVaxSafety. Monkeypox vaccine safety data. 2022. Available from: <https://ausvaxsafety.org.au/vaccine-safety-data/monkeypox-vaccine> (Accessed 09/11/2022).
27. Decker MD, Garman PM, Hughes H, et al. Enhanced safety surveillance study of ACAM2000 smallpox vaccine among US military service members. *Vaccine* 2021;39:5541-7.
28. Halsell JS, Riddle JR, Atwood JE, et al. Myopericarditis Following Smallpox Vaccination Among Vaccinia-Naive US Military Personnel. *JAMA* 2003;289:3283-9.
29. Altmann S, Brandt CR, Murphy CJ, et al. Evaluation of therapeutic interventions for vaccinia virus keratitis. *J Infect Dis* 2011;203:683-90.
30. Beachkofsky TM, Carrizales SC, Bidinger JJ, et al. Adverse Events Following Smallpox Vaccination With ACAM2000 in a Military Population. *Archives of Dermatology* 2010;146:656-61.
31. Bray M, Wright ME. Progressive Vaccinia. *Clinical Infectious Diseases* 2003;36:744.
32. Volkman A, Williamson A-L, Weidenthaler H, et al. The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform. *Vaccine* 2021;39:3067-80.
33. Rimoin AW, Mulembakani PM, Johnston SC, et al. Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. *PNAS* 2010;107:16262-7.
34. Cherry JD, McIntosh K, Connor JD, et al. Primary Percutaneous Vaccination. *The Journal of Infectious Diseases* 1977;135:145-54.
35. US Food and Drug Administration. ACAM2000 - FULL PRESCRIBING INFORMATION Package Insert. 2018. Available from: <https://www.fda.gov/media/75792/download> (Accessed 27/05/2022).
36. Hatch GJ, Graham VA, Bewley KR, et al. Assessment of the Protective Effect of Imvamune and Acam2000 Vaccines against Aerosolized Monkeypox Virus in Cynomolgus Macaques. *Journal of Virology* 2013;87:7805-15.
37. Arbel R, Sagy YW, Zucker R, et al. Effectiveness of a single-dose Modified Vaccinia Ankara in Human Monkeypox: an observational study. *Preprint on Research Square* 2022.
38. Kunasekaran MP, Chen X, Costantino V, Chughtai AA, MacIntyre CR. Evidence for residual immunity to smallpox after vaccination and implications for re-emergence. *Military Medicine* 2019;184:e668-e79.

39. Tarín-Vicente EJ, Alemany A, Agud-Dios M, et al. Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study. *The Lancet*.
40. Gallagher T, Lipsitch M. Postexposure Effects of Vaccines on Infectious Diseases. *Epidemiologic Reviews* 2019;41:13-27.
41. Massoudi MS, Barker L, Schwartz B. Effectiveness of Postexposure Vaccination for the Prevention of Smallpox: Results of a Delphi Analysis. *The Journal of Infectious Diseases* 2003;188:973-6.
42. Adler H, Gould S, Hine P, et al. Clinical features and management of human monkeypox: a retrospective observational study in the UK. *The Lancet Infectious Diseases*.
43. Centers for Disease Control and Prevention. Update: Multistate Outbreak of Monkeypox --- Illinois, Indiana, Kansas, Missouri, Ohio, and Wisconsin, 2003 (2). *Mortality Morbidity Weekly Report* 2003;52:642-6.
44. Erez N, Achdout H, Milrot E, et al. Diagnosis of Imported Monkeypox, Israel, 2018. *Emerging Infectious Disease journal* 2019;25:980.
45. Yong SEF, Ng OT, Ho ZJM, et al. Imported Monkeypox, Singapore. *Emerging Infectious Disease journal* 2020;26:1826.
46. Keckler MS, Reynolds MG, Damon IK, Karem KL. The effects of post-exposure smallpox vaccination on clinical disease presentation: Addressing the data gaps between historical epidemiology and modern surrogate model data. *Vaccine* 2013. p. 5192-201.

Appendix A Definition of severe immunocompromise

Severe immunocompromise for the purposes of mpox vaccination (both JYNNEOS® and ACAM2000™) is defined as:

- Primary immunodeficiency or acquired immunodeficiency: HIV/AIDS with CD4<200, or uncontrolled viraemia
- Haematologic neoplasms: leukaemias, lymphomas, myelodysplastic syndromes, multiple myeloma and other plasma cell disorders, post-transplant: solid organ (on immunosuppressive therapy), haematopoietic stem cell transplant (within 24 months), primary immunodeficiency,
- Receipt in the last 3 months of any of:
 - Chemotherapy or whole-body radiotherapy
 - High-dose corticosteroids (≥ 20 mg of prednisone per day, or equivalent) for at least 14 days in 1 month, or pulse corticosteroid therapy
 - Biological agents and other treatments that deplete or inhibit B- or T-cell function (anti-CD20 antibodies, BTK inhibitors, JAK inhibitors, sphingosine 1-phosphate receptor modulators, anti-CD52 antibodies, anti-complement antibodies, anti-thymocyte globulin)
 - Selected conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) including mycophenolate, methotrexate (more than 0.4 mg/kg/week), leflunomide, azathioprine (at least 3 mg/kg/day), 6-mercaptopurine (at least 1.5 mg/kg/day), alkylating agents (eg, cyclophosphamide, chlorambucil), and systemic calcineurin inhibitors (eg, cyclosporin, tacrolimus).

Appendix B Training resources for intradermal vaccine administration

Many States and Territories have developed intradermal vaccination training materials for use by immunisation providers. Some jurisdictions offer face-to-face training. Contact State and Territory public health authorities for further information.

The following are resources that may supplement jurisdictional training material. Please note that they are suggested references, and not material formally endorsed by ATAGI.

- [Victorian monkeypox vaccination program](#) (Vaccinations procedures section on pages 17-26, additional skills and competencies checklist on pages 52-53)
- [Victorian Immunisation e-Learning](#)
- Australian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM) [MPX Vaccination Training Module](#)

Appendix C Guidance for use of subcutaneous-dose JYNNEOS[®] vials as multi-dose vials for intradermal administration

JYNNEOS[®] is supplied as single subcutaneous-dose vials. With fractional (using a portion of a standard dose) intradermal dosing, this means that the original single-dose vials are being used for multiple doses.

Appendix Table 1 provides three options of procedures that can be followed to optimise safety for both the patient and the immunisation provider.

Due to the small volumes required for each intradermal dose, the use of low-dead-space syringes or low-dead-space needles is recommended to facilitate five 0.1mL doses to be withdrawn from each vial.

Appendix Table 1 – Procedures for drawing up multiple intradermal doses from a standard JYNNEOS[®] vial

Step	Method for extraction of a single dose at a time	Method for extraction of multiple doses using different needles for drawing up and administration	Method for extraction of multiple doses using the same needle for drawing up and administration
	This method is recommended whenever one or more doses will be extracted from a vial and the remaining contents of the vial will be stored. Use an aseptic technique throughout this procedure.	This method is only appropriate where multiple doses from a vial are to be drawn up in immediate succession for administration within a single vaccination session. Use an aseptic technique throughout this procedure. Vials should never be stored with a drawing up needle attached.	This method uses the same needle to draw up and administer a vaccine dose. Use an aseptic technique throughout this procedure.
A	Attach a sterile 26-27 gauge drawing up needle to a sterile syringe and insert the needle through the bung into the vial.	Attach a sterile 26-27 gauge drawing up needle to a sterile syringe and insert the needle through the bung into the vial.	Attach a sterile 26–27-gauge injection needle to a sterile syringe, and insert the needle through the bung into the vial.
B	Draw up 0.1mL for a single dose. Do not touch the shaft of the	Draw up 0.1mL for a single dose. Do not touch the shaft of the	Draw up the required volume for a single dose. Do not touch the shaft of the needle and avoid

	needle and avoid moving the needle in and out of the vial.	needle and avoid moving the needle in and out of the vial.	moving the needle in and out of the vial.
C	Remove the filled syringe with the drawing up needle attached. Do not leave the drawing up needle in the vial. Avoid touching the top of the vial.	Remove the filled syringe from the drawing up needle, leaving the drawing up needle in the bung.	Remove the filled syringe with the needle attached. Avoid touching the top of the vial.
D	Detach the filled syringe and attach a new sterile 26-27 gauge injection needle.	Attach a new sterile 26-27 gauge injection needle to the filled syringe, ready for administration to the patient. Without delay or distraction, attach a new sterile syringe to the drawing up needle to draw up each dose. Attach a new sterile 26-27 gauge injection needle to each filled syringe.	If doses are not going to be administered immediately, the needle must be resheathed (using safe aseptic technique). Repeat the procedure for all required doses.
E	Administer the dose as soon as possible after drawing up.	The prepared dose can be administered immediately or must be used as soon as practical for the next recipient. Doses drawn up into a syringe must ideally be used within 1h if kept at room temperature, or 8h if stored at 2-8°C. Until ready to be administered, store any prepared syringes at the appropriate temperature as per product information. This includes storing in a suitably sized, clean container. Label the container clearly with the date and time doses were drawn, the name of the person who	The prepared dose can be administered immediately or must be used as soon as practical for the next recipient. Doses drawn up into a syringe must ideally be used within 1h if kept at room temperature, or 8h if stored at 2-8°C. Until ready to be administered, store any prepared syringes at the appropriate temperature as per product information. This includes storing in a suitably sized, clean container. Label the container clearly with the date and time doses were drawn, the name of the person who

	<p>prepared the doses, vaccine name, age range, vial batch number, vial identifier (if available) and expiry time of drawn doses. Discard any filled syringe where there is suspicion that contamination or a sterility breach has occurred.</p> <p>Any unused doses that have been withdrawn into a syringe must be discarded after 8 hours, even if stored at 2-8°C, due to potential infection control concerns.</p>	<p>prepared the doses, vaccine name, age range, vial batch number, vial identifier (if available) and expiry time of drawn doses. Discard any filled syringe where there is suspicion that contamination or a sterility breach has occurred.</p> <p>Any unused doses that have been withdrawn into a syringe must be discarded after 8 hours, even if stored at 2-8°C, due to potential infection control concerns.</p>
--	---	---

Appendix D Jurisdictional information

Appendix Table 2 – Links to mpox information and contact details for each jurisdiction

Jurisdiction	Website
ACT	Monkeypox (MPXV) Health (act.gov.au)
NSW	Monkeypox - Fact sheets (nsw.gov.au)
NT	Monkeypox (nt.gov.au)
QLD	Monkeypox (health.qld.gov.au)
SA	Monkeypox - including symptoms treatment and prevention
TAS	Monkeypox fact sheet Tasmanian Department of Health
VIC	Monkeypox health.vic.gov.au
WA	Monkeypox virus infection - WA Health